This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
1. The H3 Biomedicine RNA splicing modulator, H3B-8800, targets the spliceosome SF3b complex containing either wild-type (WT) or mutant SF3B1.…
molecule
2 years ago ●
1 min read
2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK…
molecule
2 years ago ●
1 min read
3. The Revolution Medicines selective mTORC1 complex inhibitor, RMC-4529, is a bi-steric inhibitor that has a rapamycin-derived, FKBP12-recruiting allosteric mTOR…
molecule
2 years ago ●
1 min read
4. The Artios Pharma selective allosteric Pol_ DNA polymerase inhibitor, ART558, induces synthetic lethality in BRCA-mutant cancer cells and enhances…
molecule
2 years ago ●
1 min read
5. The Pfizer CDK2/4/6 inhibitor PF-60873600 is orally bioavailable with Ki values of 0.09 nM, 1.3 nM, and 0.16 nM…
molecule
2 years ago ●
1 min read
6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase…
molecule
2 years ago ●
1 min read
Load More
